Autonomic Pharmacology | Cholinergic Agonists

The video introduces cholinergic agonists, also known as parasympathomimetics, and emphasizes understanding the cholinergic system. It highlights that neurons in this system primarily release acetylcholine. The discussion briefly covers cranial nerves with parasympathetic fibers, including cranial nerve III (pupillary constriction, accommodation), cranial nerve VII (lacrimation, salivation), cranial nerve IX (salivation), and cranial nerve X (vagus nerve), which affects heart rate (bradycardia), bronchiole constriction, and GI secretions and motility. Additionally, it addresses sacral parasympathetic fibers influencing the lower GI and genitourinary tract (defecation, urination), and sympathetic cholinergic fibers affecting sweating. The video also touches upon cholinergic pathways in the cerebrum related to cognitive function.

Acetylcholine released from somatic motor neurons acts on skeletal muscles, causing contraction. The video differentiates between nicotinic receptors (ligand-gated ion channels) found on skeletal muscles at the neuromuscular junction and at pre-ganglionic synapses, and muscarinic receptors (G-protein coupled receptors) found on target organs like smooth muscle, cardiac muscle, and glands.

The process of acetylcholine synthesis, release, and action is detailed. Choline and acetyl-CoA combine via choline acetyltransferase to form acetylcholine, stored in vesicles. Upon nerve stimulation, acetylcholine is released and binds to receptors. For nicotinic receptors, this opens ion channels, leading to sodium influx, depolarization, and muscle contraction. Acetylcholinesterase breaks down acetylcholine, ending its effect. Drugs can act as direct agonists or indirectly by inhibiting acetylcholinesterase, increasing acetylcholine levels. The video then explains muscarinic receptor pathways, distinguishing between inhibitory (M2) and stimulatory (M3) receptors and their G-protein coupled mechanisms (Gi and Gq pathways, respectively).

Cholinergic agonists are categorized into direct and indirect types. Direct agonists (bethanacol, methacholine, pilocarpine, carbachol) directly stimulate receptors. Bethanacol, methacholine, and pilocarpine act solely on muscarinic receptors, while carbachol acts on both muscarinic and nicotinic receptors. Indirect agonists work by inhibiting acetylcholinesterase, thereby increasing acetylcholine levels. These are further divided into reversible (edrophonium, physostigmine, neostigmine, pyridostigmine, donepezil, rivastigmine, galantamine) and irreversible (ecothiopate, organophosphates like sarin, pesticides) inhibitors. The video highlights that physostigmine, donepezil, and rivastigmine are tertiary amines, allowing them to penetrate the central nervous system.

Cholinergic agonists are used to increase GI and bladder motility in conditions like post-operative ileus, postpartum urinary retention, and gastroparesis (e.g., with bethanicol, neostigmine, pyridostigmine). Methacholine is employed in bronchial provocation tests to diagnose asthma by inducing bronchoconstriction in hyper-responsive airways.

For glaucoma, drugs like pilocarpine can improve aqueous humor drainage by causing pupillary constriction (miosis) and ciliaris muscle contraction, thereby opening the canal of Schlemm and reducing intraocular pressure. Pilocarpine and carbachol also stimulate lacrimation and salivation, beneficial for conditions like Sjögren's syndrome or radiation-induced dry mouth.

In myasthenia gravis, an autoimmune disease where antibodies block nicotinic receptors, acetylcholinesterase inhibitors are used to increase acetylcholine levels, allowing it to compete with antibodies and improve muscle contraction. Edrophonium is used diagnostically in the Tensilon test due to its short action. Neostigmine and pyridostigmine are used for treatment, with pyridostigmine favored for chronic management due to its longer duration. Physostigmine is avoided due to CNS toxicity. The video also explains how edrophonium helps differentiate between a myasthenic crisis (underdosing) and a cholinergic crisis (overdosing).

Physostigmine can serve as an antidote for anticholinergic overdoses (e.g., tricyclic antidepressants, atropine). Neostigmine can reverse the effects of neuromuscular blocking agents. For Alzheimer's disease, drugs like donepezil, rivastigmine, and galantamine (tertiary amines that cross the blood-brain barrier) inhibit acetylcholinesterase in the brain, increasing acetylcholine levels to improve cognitive function and memory, though they only slow disease progression, not cure it.

A cholinergic crisis results from excessive cholinergic stimulation, leading to symptoms like pinpoint pupils (miosis), increased lacrimation, profuse salivation, bradycardia, bronchospasm, increased GI motility (diarrhea), increased urination, muscle weakness, convulsions, agitation, and sweating. The mnemonic 'DUMBBELLS' helps remember these symptoms. Antidotes include atropine (an anticholinergic agent) and pralidoxime, particularly for irreversible acetylcholinesterase inhibitors like organophosphates, but only if administered before 'aging' of the enzyme occurs.

The video concludes with a series of practice questions to test understanding of cholinergic agonists, their mechanisms, and clinical applications, covering topics such as botulinum toxin's effect, treatment for urinary retention, drugs affecting asthma, pupillary dilation, Alzheimer's treatment, cholinergic crisis, and reversal of neuromuscular blockers and atropine poisoning.